Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02260180 · ClinicalTrials.gov registry record · Phase 2
Study of A-101 for the Treatment of Seborrheic Keratosis
A Phase 2 study, sponsored by Aclaris Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 119
- Enrollment target
NCT02260180: Completed Phase 2 study, sponsored by Aclaris Therapeutics.
NCT02260180 is a Phase 2 study that has completed, run by Aclaris Therapeutics. The registered enrollment target is 119 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (11% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02260180, a Phase 2 study, has completed, sponsored by Aclaris Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 119 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and dose-response of 2 concentrations of A-101 versus a vehicle control in the treatment of seborrheic keratosis.
Primary Outcome
The primary effectiveness analysis was a comparison between each A-101 group and the vehicle group based on the percentage with target lesions judged to be clear on the PLA (PLA = 0) at Visit 8. The three arms of the study are A-101 40% Topical Solution, A-101 32.5% Topical Solution, and A-101 0% Topical Solution (vehicle). The Physician's Lesion Analysis ( PLA) is a 4 point scale from 0 to 3, with 0 being lesion clear and 3 being the most severe lesion. A larger proportion of subjects with a PL
Interventions
- DRUG A-101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 119 participants |
| Start Date | 2014-10 |
| Est. Completion | 2015-03 |
| Phase | Phase 2 |
What the finished NCT02260180 record still lists
NCT02260180 is an interventional study that assigns participants to a tested intervention. The registered 119 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (11% lower).
The record links to 0 conditions, and to 1 intervention - of which A-101 is the first listed.
NCT02260180 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02260180 about?
NCT02260180 is a clinical study titled "Study of A-101 for the Treatment of Seborrheic Keratosis". The purpose of this study is to evaluate the safety and dose-response of 2 concentrations of A-101 versus a vehicle control in the treatment of seborrheic keratosis.
What is the current status of trial NCT02260180?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 119 participants. The study started on 2014-10. Estimated completion is 2015-03.
What interventions are being tested in trial NCT02260180?
The interventions under investigation include: A-101 (DRUG).
Who is sponsoring clinical trial NCT02260180?
This trial is sponsored by Aclaris Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02260180's enrollment target sits among peer trials
119 618th of 2000 higher than 1,383 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04870762 · 119 participants · Phase 2
Customized 3D Printed Oral Stents During Head and Neck Radiotherapy
- NCT05559853 · 119 participants
Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment
- NCT06564389 · 119 participants · Phase 1
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
- NCT06742801 · 119 participants · NA
Onyx™ Liquid Embolic IDE Clinical Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia